NCT07334145

Brief Summary

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
4mo left

Started Jan 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress52%
Jan 2026Sep 2026

First Submitted

Initial submission to the registry

December 31, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 12, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

January 14, 2026

Status Verified

January 1, 2026

Enrollment Period

6 months

First QC Date

December 31, 2025

Last Update Submit

January 13, 2026

Conditions

Anemia in CKD Patients

Outcome Measures

Primary Outcomes (2)

  • hemoglobin level

    use the hemoglobin level to assist the effect of SGLT2 inhibitors On anemia correction

    12 weeks

  • change in hemoglobin level

    anemia correction

    12 weeks

Study Arms (1)

CKD patients stage 1_4

Drug: SGLT2 inhibitor

Interventions

SGLT2 inhibitorDRUG

prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

CKD patients stage 1_4

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

people in sohag twen

You may qualify if:

  • age more than 18 years
  • CKD stage 1\_4
  • baseline hemoglobin 8.5 to 12.9 g/dl
  • stable anemia regimen for more than 8 weeks

You may not qualify if:

  • dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University Hospital

Sohag, Sohag University, Egypt

Location

MeSH Terms

Interventions

Sodium-Glucose Transporter 2 Inhibitors

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesHypoglycemic AgentsPhysiological Effects of Drugs

Study Officials

  • Romany Naguib Mikhaeil, master

    Sohag University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Romany Naguib Mikhaeil, master

CONTACT

01274426883romanynaguib977@gmail.com

Ahmed Nagah NourEldin, associate professor

CONTACT

01127022717ahmednagah3000@yahoo.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident of internal medicine at sohag university hospital

Study Record Dates

First Submitted

December 31, 2025

First Posted

January 12, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

January 14, 2026

Record last verified: 2026-01

Locations

EG(1)